Research Library

The recent shift toward legalization has not been enough to undo the racism endemic to U.S. cannabis policy. The authors lay out policies to improve equity and erase the racist legacy of prohibition.

Although Texans broadly support relaxing cannabis laws and other criminal justice reforms, state leaders continue the war on drugs and other policies that propagate systemic racism, writes fellow Katharine Neill Harris.

Special purpose acquisition companies (SPACs) have experienced a massive surge in popularity over the last year. How do SPACs work, and what are some of the tax implications that investors may overlook? Public finance fellow Joyce Beebe explains on the Baker Institute Blog: https://bit.ly/3t5eMH8

Restrictions in Texas' medical cannabis law keep most of the state's patients from participating. Our survey of 2,866 Texas residents who use medical cannabis sought to gain insight into the needs and experiences of this population.

Fellow Katharine Neill Harris testified before the U.S. House Judiciary Committee on the failed war on drugs and solutions based on racial justice and harm reduction.

Effective drug policy requires acceptance that, for better or worse, licit and illicit drug use is part of our world. The authors recommend several steps the federal government can take to facilitate more pragmatic and effective drug policy at all levels of government.

An overview of the ABA's Cannabis Law & Policy Committee, which is composed of attorneys across North America who have various mainstream practices and who seek to be stewards of historic changes in the pioneering field of marijuana law.

The authors examine recent trends in vaping, research on its effectiveness for smoking cessation, the role of industry marketing and policy responses to increased use.

According to the authors, as a leading agricultural state, Texas is poised to become the new leader in hemp production, whether for medicinal or industrial purposes.

Products containing hemp extracts high in CBD are gaining mainstream popularity, acceptance and federal legality. In this article, Lisa Pittman, nonresident fellow in drug policy, focuses on litigation issues particular to hemp.